Injured by recalled DePuy ASR and Pinnacle Hips? Metallosis, pain and suffering, hip replacement? Read More Here >>
Injured by recalled Stryker Rejuvenate and ABG II Hips? Metallosis, pain and suffering, hip replacement?Read More Here >>
Injured by Metal on Metal Hips, Biomet M2A Magnum, Smith and Nephew, Wright Conserve? Metallosis, pain and suffering, hip replacement? Read More Here >>
Injured by Trans Vaginal Mesh complications following Pelvic Organ Prolapse and Urinary Incontinence surgery? Pain and suffering, redo surgery, urinary incontinence? Read More Here >>
Injured by Mirena IUD complications? Mirena uterus perforation and uterus imbedment requiring surgery? We can help, Read More Here >>
Injured by Actos Bladder Cancer? We can help, Read More Here >>
Injured by Pradaxa Hemorrhage or Stroke?We can help, Read More Here >>
Injured by NuvaRing Deep Vein Thrombosis, Pulmonary Embolism, Stroke? We can help, Read More Here >>
Injured by Januvia/Byetta/Victoza Pancreatic Cancer?We can help, Read More Here >>
Birth Defects by Zoloft/
SSRI Antidepressants?
We can help, Read More Here >>

Dr Shezad Malik Law Firm has offices based in Fort Worth and Dallas and represents people who have suffered catastrophic and serious personal injuries including wrongful death, caused by the negligence or recklessness of others. We specialize in Personal Injury trial litigation and focus our energy and efforts on those we represent.

Published on:

A Texas woman is the latest to sue Bayer and Johnson & Johnson pharmaceutical companies, claiming that the anticoagulant Xarelto has inadequate warnings about the bleeding risk associated with the drug. Jeanne Jeffcoat filed the lawsuit in the U.S. District Court for the Eastern District of New York, she claimed that Xarelto caused life-threatening bleeding event that left her permanently injured.

xarelto side effects attorneyThere are many defective drug product liability lawsuits filed nationwide over bleeding and hemorrhage side effects of Xarelto.

Xarelto Aggressive Marketing

Plaintiffs are alleging that the drug makers aggressively marketed Xarelto as superior to warfarin without warning about the risk of bleeding and the lack of an antidote to reverse the blood thinning effects of the medication.

Jeffcoat began using Xarelto in March 2012, and 4 months later she suffered a life-threatening bleed that has left her with severe, permanent injuries, and pain and suffering.

What is Xarelto?

Xarelto (Rivaroxaban) is a new type of anticoagulant, known as “direct thrombin inhibitors,” which are used to reduce the risk of blood clots, deep vein thrombosis, pulmonary embolism and embolic strokes. The drug was developed by Bayer and Janssen and was approved in 2011.

Xarelto Misleading Marketing Claims

The lawsuit alleges that the companies purposefully mislead the doctors. Plaintiffs claim that the drug makers withheld information from patients and doctors about the lack of an antidote and about the severe bleeding risks with Xarelto.

The companies promoted three medical studies to get Xarelto approved as a stroke preventative for patients with atrial fibrillation, deep vein thrombosis and pulmonary embolism. All of the studies demonstrated an increased risk of serious bleeding events.

According to the lawsuit, the companies used the studies’ positive results to promote Xarelto to doctors in their promotional materials, but the “promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion, among other serious bleeding concerns.”

The companies allegedly spent at least $11 million on advertising in medical journals in 2013 alone, making Xarelto the number one pharmaceutical product advertised in professional health journals in the third quarter of 2013 based on pages and money spent.

Xarelto: No Reversal Agent

Xarelto was designed to replace Coumadin (warfarin) for the prevention of stroke in patients with atrial fibrillation. Atrial fibrillation is a common heart rhythm problem that increases the risk of strokes. All blood thinners increase the risk of suffering a bleeding event, but warfarin’s blood thinning side effects can be reversed with vitamin K.

Xarelto has no reversal agent. The lawsuit claims that the FDA had to issue a warning on June 6, 2013, saying that the companies direct to consumer ads were misleading because they minimized the risk of uncontrollable bleeding.

According to the FDA, the companies downplayed the risks and placed them so that they would not catch readers’ attention. Furthermore made misleading claims that there were no dosage adjustments required, when in fact there were.

Xarelto Scope of Bleeding Problems

According to the lawsuit, “In the year leading up to June 30, 2012, there were 1,080 Xarelto-associated ‘Serious Adverse Event’ (‘SAE’) Medwatch Reports filed with the FDA, including at least 65 deaths.”

The lawsuit goes on to allege, “At the close of the 2012 fiscal year, a total of 2,081 new Xarelto-associated SAR reports were filed with the FDA in its first full year on the market, ranking tenth among other pharmaceuticals in direct reports to the FDA. Of those reported events, 151 resulted in death, as compared to only 56 deaths associated with warfarin.”

According to the reports, Xarelto bleeding problems result in death in 8% of all cases, which is double the rate of death for warfarin bleeding events.

The Institute for Safe Medication Practices warned that the figures indicated a “strong signal” that there were safety problems with Xarelto and said that the public and scientific community needed to be warned and Xarelto safety needed to be further investigated.

Published on:

There are several thousand lawsuits filed by folks both in state and federal courts by patients who took the prescription drug pioglitazone, sold as brand name Actos and later developed bladder cancer. Doctors prescribe Actos to treat patients with Type 2 Diabetes.

Actos_Bladder_Cancer_AttorneyTakeda Actos Bladder Cancer Verdict

On April 7, 2014, a federal jury in Louisiana found Takeda failed to adequately warn about bladder cancer risks of Actos. Jurors also found that executives of Takeda acted with wanton and reckless disregard for patient safety and awarded a total of $9 billion in punitive damages.

Actos Bladder Cancer Link & FDA Warnings

In June 2011, the U.S. Food and Drug Administration announced a drug safety alert warning that the use of Actos for more than one year may be associated with an increased risk of bladder cancer. The FDA released a “Drug Safety Communication,” indicating that based on dose and duration of use, there exists a 40 percent increased risk of developing Actos bladder cancer.

Health authorities in France also suspended the use of Actos due to the risk of developing bladder cancer.

In April 2012, Health Canada, the government drug safety agency for Canada, announced a safety warning on Actos. Diabetes patients prescribed Actos for over a year had two times higher risk of bladder cancer than diabetes patients not taking Actos.

One of the most recent studies on Actos and bladder cancer was published in the British Medical Journal, May 2012 issue.

Researchers studied 115,727 patients and discovered that Actos use increased the risk of bladder cancer by 83 percent. They also noted that the risk increases with long-term use of Actos.

Actos Cancer Side Effects Lawsuits

Manufacturers of prescription drugs have a duty to patients to produce safe products and to warn patients and their doctors of any adverse health effects. The lawsuits filed by Actos patients with bladder cancer allege that Takeda breached both of these duties and Takeda is legally responsible for the harm and must pay damages.

Takeda Knew About Bladder Cancer Risk

The Actos complaints allege that Takeda had studies on laboratory animals showing an increased risk of bladder cancer when the animals were provided the drug. Takeda allegedly failed to disclose these laboratory test results to health regulators.

Actos was released in 1999, and the FDA directed Takeda to undertake a post-marketing study on the safety and effectiveness of Actos. Takeda allegedly delayed initiating the study until 2003 and designed the study as a 10-year trial. Because of this study design, the final results will not be available until after the expiration of Takeda’s exclusive patent on Actos.

Early results published in 2011 did show increased risk of bladder cancer.

Published on:

For those patients who have been implanted with either a Stryker Rejuvenate or ABG II artificial hipmetal  implant, I have an important update to share regarding the status of the defective hip product liability lawsuits and the Stryker hip litigation in general.

Stryker Rejuvenate Hip Recall attorneyWhat is Stryker Rejuvenate Hip?

The Stryker Rejuvenate is a modular metal based hip replacement, and was recalled from the market in July 2012, after the company indicated that it is subject to fretting, corroding and finally failing shortly after it is implanted.

The Stryker Rejuvenate has a modular neck-stem, with two components that fit inside of each other to allow the surgeon to adjust the length of the femoral component based on the patient’s physical dimensions. This design has been associated to an increased risk of metallosis that occurs from the release of metal debris as the chromium-cobalt neck grinds against the titanium femoral stem.

According to experts, approximately 20,000 patients received the metal hip implants. 4,000 defective hip product liability lawsuits have been filed across the U.S.

Federal Multidistrict Litigation

1,700 cases are pending in the federal court system, and consolidated as part of an MDL, or multidistrict litigation. Here the Stryker Rejuvenate lawsuits are centralized before U.S. District Judge Donovan Frank in the District of Minnesota to reduce discovery, avoid conflicting pretrial rulings and to serve the convenience of the parties.

New Jersey State Multidistrict Litigation

Consolidated pretrial proceedings have been established in New Jersey state court, since is the corporate state for the hip manufacturer, Howmedica Osteonics.

Stryker Rejuvenate Settlements

In both New Jersey and the federal court system, some cases are being prepared for early trial dates, known as “bellwether” cases. If a Stryker Rejuvenate hip settlement is not reached to resolve the litigation, these trials are expected to begin in 2015.

Court-ordered mediation programs are also underway to settle small groups of cases. According to the New Jersey state court overseeing the litigation, settlement has been reached in 19 cases out of the 21 that have gone through the mediation program.

Recently, Stryker announced it had taken a $161 million charge relating to costs of the Rejuvenate and ABG II recall. The company warned investors that those costs were not paid for by its insurance proceeds.

Published on:

There has been some success in the lawsuits involving thousands of defective metal on metal hips. Some of the lawsuits have been settled and thousands more are still pending against the metal hip manufacturers including Zimmer (now the new proud owner of Biomet), DePuy, Stryker, Wright Medical and Smith and Nephew that sold the metal-on-metal hip implants.

DePuy ASR Metallosis Injury AttorneyThe defective hip replacement lawsuits share similar allegations that there is premature hip implant failure caused by metal cobalt and chromium release. The artificial hips are made of cobalt chromium alloy and the grinding action of the hip joint in daily activity causing the metal components to rub together, leading to the release of these toxic heavy metal particles.

The release of these metal ions , causing metallosis, damaging tissues in the hip area and causes elevated blood levels of these toxins.

Settlements Underway For DePuy ASR

In July 2014, Johnson & Johnson and DePuy Orthopaedics Inc., a subsidiary of J&J, began payments in the $2.5 billion DePuy ASR metal hip implant settlement that was announced in November 2013. The settlement involves approximately 8,000 cases (all of whom were required to have revision surgery before August 13, 2013) with base payments of $250,000 per case. Patients with hip implants older than 5 years, smokers and overweight folks would get less.

DePuy Pinnacle Trials On Track

As of July 2014, more than 6,400 DePuy Pinnacle lawsuits continue to grind forward in U.S. District Court, Northern District of Texas. U.S. District Judge Ed Kinkeade granted part of a motion filed by the Plaintiffs’ Steering Committee that wanted the deposition of a witness and production of certain documents related to the Deferred Prosecution Agreement entered into between DePuy and the U.S. Department of Justice in April 2011. The first bellwether trials are set for September 2014.

Zimmer and Biomet Settlements

In 2010, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated federal Zimmer metal-on-metal Durom Acetabular Cup cases into multidistrict litigation (MDL No. 2158). Zimmer has settled with its Durom Cup with a $400 million payout and plans to continue settling with Zimmer hip replacement patients.

In February 2014, Biomet Inc., which is now owned by Zimmer, agreed to a $56 million settlement for its M2a 38 and Magnum models metal-on-metal hip replacements. The average settlement amount for each Biomet hip case is approximately $200,000. More than 1,600 Biomet hip replacement lawsuits have been filed in the US District Court, Northern District of Indiana. Patients with hip implants older than 5 years, smokers, cases filed after the statute of limitations and overweight folks would get less.

Stryker Hip Settlement

Stryker Corp. recalled its ABG II and Rejuvenate Hip Model Systems in July 2012 and there are 20,000 Stryker hip implanted nationwide. According to some experts, the artificial hip failure rate could be as high as 50 percent.

In the fall of 2013, several Stryker cases began mediation. Either a global settlements will be announced soon or the first bellwether trials could be set. Stryker is exposed to more than 1,000 hip lawsuits in state and federal courts, and more than 500 cases have been designated as MDL in New Jersey.

Wright Medical Technology Inc.

Wright Profemur and Conserve Hip Replacement Implants have not been recalled but a number of lawsuits nationwide have been filed against Wright. No settlements have been announced to date.

Smith and Nephew R3

Smith and Nephew Implants have not been recalled, except for a limited number of R3 models and a number of lawsuits nationwide have been filed against Smith and Nephew. Smith & Nephew initiated a worldwide recall of the metal liner in its R3 Acetabular System in 2012, after reports of loosening, pain, device failure, infection, metal sensitivity and dislocation. Almost 4,000 of the metal liners were used in the United States between 2009 and the recall. No settlements have been announced to date.

Published on:

According to a new report by the U.S. Centers for Disease Control and Prevention (CDC), 25% of fatal automobile accidents are associated with drivers who were tired or fell asleep behind the wheel. There are significant and deadly risks associated with drowsy driving.

car_crash_0188In the most recent U.S. Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR), a study demonstrated that at least one out of every 25 drivers admitted to falling asleep behind the wheel over the last month.

Binge Drinking Risk

According to the survey, 4.0% of respondents reported falling asleep while driving during the previous 30 days. Those who engaged in binge drinking were often more likely to be drowsy behind the wheel. The effects of the alcohol from binge drinking commonly cause “hangover” like symptoms leaving drivers less alert and causing delayed reactions.

Lack of Sleep Risk

Sleep deprivation was also a factor, the respondents who usually slept less than five hours a day reported drowsy driving more often than those who got in at least six hours of sleep per day. Drivers who got less sleep were also less likely to buckle up.

The CDC has indicated while drowsy driving typically causes single vehicle accidents where the driver goes off the road, sleep-related crashes are also disproportionately represented in rear-end and head-on collisions.

Many times drivers who “nod off” at the wheel cause head-on accidents at accelerated speeds with oncoming traffic if there is no median or barrier wall, frequently ending with fatalities.

CDC Recommendations and Tips

  • Make sure you get enough sleep before getting behind the wheel.
  • Avoid alcohol or other sedatives before driving
  • Break up long driving trips with naps
  • Drink coffee if feeling tired while driving
  • Avoid driving late at night
  • Pull over immediately if you feel yourself dozing off.

The CDC recommends drivers be watch out for signs that fatigue is affecting your driving such as frequent yawning, drifting from your lane, missing exits, and difficulty remembering the last few miles you just drove.

Published on:

After a record breaking pharmaceutical $9 billion jury verdict involving Actos bladder cancer lawsuit, Takeda Pharmaceuticals and Eli Lilly, Actos manufacturers, have filed for a new trial. Takeda Pharmaceuticals and Eli Lilly, claim that the massive award shows that the jury acted with “passion and prejudice”.

Actos_Bladder_Cancer_AttorneyActos Record $9B Verdict

In April, a federal jury in Louisiana hammered Takeda with $1.5 million in compensatory damages and a whopping $9 billion in punitive damages. Terrance Allen and his wife’s claim, was the first out of several thousand Actos lawsuits in the federal court system to go to trial.

The plaintiff complaints allege that the Takeda and Eli Lilly hid critical information from patients and the doctors about the risk of developing bladder cancer from Actos side effects.

The punitive damage award, was designed to punish Takeda and Eli Lilly for putting profits before patients in recklessly endangering patients’ lives.

Defense Claims for New Trial

“Defendants are entitled to a new trial because the jury’s multi-billion dollar punitive damages awards are unconstitutional and so excessive as to per se demonstrate passion and prejudice,” the petition for a new trial states. “At the very least, the Court should remit the punitive damages awards to amounts that total no more than compensatory damages.”

Actos Federal Bellwether MDL Trials

The Allen trial was the first in a series of “bellwether” cases in the federal court system, there are 3,000 other Actos bladder cancer cases pending.

Bellwether cases are designed to reduce duplicative discovery, allow the juries to weigh similar evidence and testimony that will be offered in other cases. The aim is to facilitate Actos settlement negotiations that may avoid the need for hundreds of individual trials.

Takeda Acted in Bad Faith

Evidence presented during the Allen trial, included internal memos revealing that Takeda Pharmaceutical executives knew about the bladder cancer risks before Actos was even on the market.

U.S. District Judge Rebecca Doherty ruled that Takeda has acted in bad faith during the litigation and failing to properly preserve evidence relevant to the cases.

On June 20, Judge Doherty went even further, saying that plaintiffs and the court have now presented sufficient evidence to establish that Takeda Pharmaceuticals intentionally deleted or destroyed documents and other evidence.

Actos and Bladder Cancer Link

Actos (pioglitazone) is a type 2 diabetes drug that has been used by millions of Americans. Medical reports in 2010 demonstrated a link between Actos and bladder cancer, paving the way for thousands of product liability lawsuits being filed against the drug makers for failure to research the medication or provide sufficient warnings to patients and the doctors.

Actos State Court Verdicts

In May 2013, a California jury awarded $6.5 million in an Actos bladder cancer case brought by Jack Cooper. But, post-trial that verdict was reversed because the state court judge excluded the plaintiffs’ expert witness testimony.

In September 2013, in a second trial in Maryland state court, the jury found that Takeda failed to warn about the risk of bladder cancer and awarded $1.77 million in damages. But, under Maryland law of contributory negligence, since the jury also found that the plaintiff contributed to the cancer by smoking, that case ended with a defense win.

A third Actos bladder cancer trial in Nevada state court, resulted in a defense verdict after the jury determined that both Actos and the plaintiff’s history as a smoker contributed to the development of bladder cancer.

Another trial involving two plaintiffs in Las Vegas earlier this year also resulted in defense verdicts.

Published on:

A Massachusetts state jury found for the defense, in the first of more than 20,000 transvaginal mesh lawsuits filed against Boston Scientific. The plaintiff, Diane Albright, claimed that Boston Scientific Pinnacle transvaginal mesh was defective and caused her to suffer significant and painful pelvic injuries.

vaginal mesh injury lawyer-thumbThe Massachusetts jury found that Albright failed to prove her claim that the Boston Scientific mesh was defective or that inadequate warnings were provided about the risk of complications.

This case was the first Boston Scientific mesh lawsuit to go before a jury, and several Boston Scientific mesh trials are expected later next year. In Massachusetts state court, there are 1,700 cases against Boston Scientific, and the next trial is expected to begin on August 11.

West Virginia Mesh MDL

Most of the mesh cases filed nationwide against Boston Scientific are filed in the federal court system. There are more than 12,000 complaints that have been centralized as part of a multidistrict litigation (MDL) before U.S. District Judge Joseph Goodwin in the Southern District of West Virginia.

On November 3, the first federal Boston Scientific mesh trial is set to start. This trial involves a consolidation of 11 different lawsuits and the Boston Scientific Obtryx sling for repair of stress urinary incontinence (SUI)

The court has ordered that a second wave of Boston Scientific bellwether cases in the MDL be prepared for early trial dates by January 2015.

TransVaginal Mesh Litigation

Nationwide, more than 60,000 women have filed lawsuits after suffering complications with vaginal mesh or bladder sling products used to repair pelvic organ prolapse (POP) or female stress urinary incontinence (SUI).

According to the latest case list as of July 15, the federal court is handling 12,500 Bard Avaulta mesh, 18,501 Ethicon mesh, 17,901 American Medical Systems (AMS) mesh, 1,506 Coloplast mesh, 213 Cook Medical mesh and about 74 Neomedic mesh lawsuits.

Mesh Trials and Settlements

The first federal vaginal mesh trial began in July 2013, against C.R. Bard involving their Avaulta mesh product. That case resulted in a $2 million damage award for Donna Cisson, including $1.5 million in punitive damages.

Bard has agreed to settle at least two federal cases shortly before trial was scheduled to begin before Judge Goodwin. Earlier in July, a settlement of an additional 500 cases was announced for an undisclosed amount. A second wave of 200 cases involving Bard Avaulta mesh are also now being prepared for additional trial dates early next year.

In June, Endo Health Solutions decided to settle AMS mesh lawsuits for an estimated $830 million, avoiding a series of bellwether trials set to begin over this summer.

Published on:

A Vermont man who suffered deadly brain bleed has filed a wrongful death lawsuit. The family alleges that the death was caused by side effects of Xarelto, a new generation anticoagulant. Xarelto, has recently come under fire from its irreversible bleeding side effects and is the subject of many similar lawsuits.

xarelto side effect attorneyThomas C. Dunkley’s daughter Ruth McGowen, filed a claim against Bayer Healthcare and Johnson & Johnson’s Janssen Pharmaceuticals subsidiary on July 25, in the U.S. District Court for the District of Vermont.

According to the Xarelto allegations, Dunkley was prescribed the blood thinner anticoagulant in July 2012, for treatment of atrial fibrillation to reduce the risk of a embolic stroke.

After using the medication for less than ten days, Dunkley suffered catastrophic brain bleeding or hemorrhage from Xarelto, which was irreversible. Dunkley ultimately died on August 1, 2012.

Xarelto Hemorrhage Lawsuits

There are Xarelto bleeding lawsuits being filed throughout the U.S., that allege patients suffered catastrophic and deadly injuries as a result of unstoppable hemorrhaging while on the anticoagulant. Xarelto, like another controversial anticoagulant Pradaxa, does not have an approved reversal agent to stop the medication’s blood thinning effects.

What is Xarelto?

Xarelto (Rivaroxaban) is a new generation anticoagulant, known as “direct thrombin inhibitors,” which are used to reduce the risk of blood clots, deep vein thrombosis, pulmonary embolism and embolic strokes. The drug was jointly developed by Bayer and Janssen, and was approved in late 2011.

Plaintiff Xarelto Allegations

Plaintiffs allege that the drug makers withheld information from consumers and doctors about the lack of an antidote and about the catastrophic bleeding risks with Xarelto.

According to Ruth McGowen, the drug makers put profits before patient safety, and that Bayer and Janssen spent $11 million promoting the drug in 2013 in medical journals alone.

Xarelto Aggressive Marketing Push

Xarelto is aggressively touted as a superior alternative to warfarin, which has been the standard anticoagulation treatment for many years. As a result of the aggressive marketing push, Xarelto generated $582 million in worldwide sales during the first year on the market and total sales reached about $2 billion last year.

Xarelto No Antidote

Allegedly Bayer and Janssen withheld information that there is no Xarelto antidote like there is for warfarin.

According to McGowen claims, “As part of their marketing of Xarelto, Defendants widely disseminated direct-to-consumer advertising campaigns that were designed to influence patients, including Decedent, to make inquiries to their prescribing physician about Xarelto and/or request prescriptions for Xarelto. In the course of these direct-to-consumer advertisements, Defendants overstated the efficacy of Xarelto with respect to preventing stroke and systematic embolism, failed to adequately disclose to patients that there is no drug, agent, or means to reverse the anticoagulation effects of Xarelto, and that such irreversibility could have permanently disabling, life-threatening and fatal consequences.”


Published on:

An Illinois woman has filed a lawsuit against Johnson & Johnson over their talcum powder products. Lynne Cebulske alleges that she developed ovarian cancer after using Johnson’s Baby Powder and Shower to Shower body powder for feminine hygiene purposes.

J&J Talcum Powder Ovarian Cancer attorneyCebulske filed the complaint in St. Clair County Court in Illinois on May 14. Throughout the United States there are a growing number of talcum baby and body powder lawsuits filed by women who allege that Johnson & Johnson failed to warn about the ovarian cancer risk associated with the talcum products.

Cebulske was diagnosed with ovarian cancer on May 14, 2012, after using Johnson & Johnson’s talcum powder products since 1992.

What is Johnson’s Baby Powder and Shower-to-Shower?

Johnson’s Baby Powder and Shower-to-Shower are talcum-based products that have been promoted for female hygiene. Recent medical studies have indicated that use of the powders as a female hygiene product may cause talc particles to migrate through the vagina to the uterus, fallopian tubes and ovaries causing ovarian tumors.

Medical Studies: Link between Talc Genital Use and Ovarian Cancer

In June 2013, a study published in the medical journal Cancer Prevention Research found that women who used talc genital powder may face a 20% to 30% higher risk of ovarian cancer than those who do not.

The International Agency for Research on Cancer, has classified genital use of talc powder as a “possible carcinogen,” and the American Cancer Society has indicated women concerned about the talcum powder cancer risk may want to avoid these products.

Talc Ovarian Cancer Lawsuits

In April 2014, a talcum powder class action lawsuit was filed against Johnson & Johnson, alleging that the company failed to adequately warn consumers about the potential risk of ovarian cancer from Johnson’s Baby Powder. Plaintiffs in that case maintain that talcum baby powder is not safe for use as a feminine hygiene product, and that Johnson & Johnson has withheld information about the link to ovarian cancer for decades.

In October 2013, a South Dakota jury found that Johnson & Johnson failed to adequately warn about the risk of ovarian cancer from talcum powder products. The woman was diagnosed with cancer in 2006 after using Shower-to-Shower body powder for 30 years.

Cebulske raises similar allegations to those brought by other women, pursuing claims for failure to warn, negligence, breach of warranty, and civil conspiracy. She is seeking compensatory damages in excess of $350,000.

Published on:

David Lyon from Texas recently filed a product liability personal injury lawsuit against the makers of Androgel. Lyon alleges that testosterone gel side effects caused a myocardial infarction or heart attack and that the manufacturer mislead consumers that the drug was safe.

Testosterone Androgel Lawsuit

Lyon filed his lawsuit in the U.S. District Court for the Northern District of Illinois on June 2. Lyon claims that AbbVie, Inc. and Abbott Laboratories withheld important information from patients and doctors about the risk of heart attacks and other blood clot injuries from Androgel use.

According to Lyon, he was prescribed Androgel in January 2005, for low testosterone symptoms. He claims that he had no prior history of cardiac problems until he suffered a significant myocardial infarction from Androgel in November 2005.

Hundreds of Testosterone Lawsuits Filed

Many Androgel lawsuits have been filed by men nationwide who have suffered heart attacks, strokes, blood clots including life-threatening pulmonary embolism and deep vein thrombosis injuries that were allegedly caused by the popular testosterone gel.

Plaintiff Claims Fraud

Lyon accuses AbbVie of duping men with a manufactured disease that they called “Low-T.” As men age, the side effects of aging, like fatigue and lowered libido and reduced testosterone levels are common place. Testosterone supplements are only indicated for a medical condition known as hypogonadism, which causes abnormally low testosterone levels.

Lyon is pursuing claims for failure to warn, breach of warranty, negligence, fraud, negligent misrepresentation, and seeks compensatory and punitive damages.

Testosterone Litigation

Many testosterone lawsuits have been filed in recent months against AbbVie and makers of other similar drugs, after a series of studies revealed the link between testosterone and cardiovascular risks.

In November 2013, a study published in JAMA demonstrated that side effects of low T drugs may increase the risk of heart attacks, strokes, and death among older men with certain pre-existing heart problems.

A study published in the medical journal PLOSOne in January 2014, found that low T treatments may double the risk of heart attack for younger men with heart disease and men over the age of 65, regardless of their prior heart conditions.

FDA Warning and Investigation

The FDA launched a safety review of all testosterone replacement therapy on January 31. Most of the lawsuits filed to date have involved injuries associated with the use of AndroGel, which is a testosterone gel spray manufactured and sold by AbbVie.

Other cases are being filed by men who suffered BLOOD CLOT injuries following use Axiron and other testosterone products, including Testim, Foresta, AndroDerm and others.

Testosterone Multidistrict Litigation, MDL

In May a motion was filed for all testosterone drug lawsuits to be centralized as part of one consolidated proceeding during pretrial litigation. Known as multidistrict litigation or MDL, this process reduces duplicative discovery and avoids conflicting rulings from different judges.

The U.S. Judicial Panel on Multidistrict Litigation (JPML), which oversees MDL consolidations, heard oral arguments over the AndroGel consolidation motion on May 29. It is expected to issue a ruling in the near future.